Written by me, refined by Gemini.

UnitedHealth Group (UNH) released their Q1 2026 results recently, and the data suggests a significant shift in operational performance compared to the volatility seen in 2024. Instead of relying on management narratives, let's look at the actual divergence between expectations and results.

The Earnings Snapshot

The 2024 fiscal year was clearly a trough, heavily impacted by the Change Healthcare cyberattack and non-recurring divestitures. Looking at the EPS trajectory helps frame the current recovery.

|Fiscal Year|Reported/Projected EPS|Status| |:-|:-|:-| |2023|$23.86|Actual| |2024|$15.51|Actual (Impacted Year)| |2026|>$18.25|Guidance (Projected)|

The "Beat" and Expectation Shift

The most interesting aspect of the Q1 2026 report isn't just the beat—it’s how the operational metrics (specifically the Medical Care Ratio) influenced the guidance adjustment. The market was expecting a more conservative Q1, and the reality forced an upward revision in the company's full-year outlook.

|Metric|Consensus Estimate|Actual Results|Delta / Context| |:-|:-|:-|:-| |Q1 2026 EPS|$6.59|$7.23|~9.7% Positive Surprise| |Q1 2026 Revenue|$109.44B|$111.7B|~2% YoY Growth| |FY 2026 Guidance|~$18.00|>$18.25|Upward Revision|

Key Takeaway: MCR Discipline

Rather than taking management's word that "things are going well," the metric that actually matters here is the Medical Care Ratio (MCR).

• Q1 2025 MCR: 84.8% * Q1 2026 MCR: 83.9%

A 90-basis-point improvement in MCR is the primary driver behind the earnings beat. They are successfully managing their medical costs relative to premiums. The "recovery" narrative holds weight only because the margin discipline has returned, not because of top-line revenue expansion or executive promises.

The company is trading at a point where the market is pricing in the stabilization. If the MCR holds below 84% for the remainder of the year, the guidance of >$18.25 looks conservative.